ライフサイエンスコーパス: per

1 HR of 1.52 (95% CI, 1.39 to 1.67; I(2) = 0%) per 0.1 unit.

2 6), low CSF to blood glucose ratio (HR, 1.16 per 0.10 decrease; 95% CI, 1.04-1.30), CSF culture posit

3 apid warming since 1985, and shows with 33 m per 1 degrees C, the most intense upward shift.

4 sed from an average of 13.8 days to 9.4 days per 1,000 patient-days (P = 0.009).

5 nce rates with 95% confidence intervals (CI) per 1,000 person-years were as follows: non-biologic, 14

6 eline, with an overall incidence rate of 2.8 per 1,000 person-years.

7 PMI countries was reduced from 28.9 to 24.3 per 1,000 person-years.

8 We defined incident CKD as eGFR<60 ml/min per 1.73 m(2) and >/=30% eGFR decline at the third visit

9 participants with baseline eGFR >/=60 ml/min per 1.73 m(2) At baseline, mean age was 55 years old, 37

10 ipants were men, and mean eGFR was 94 ml/min per 1.73 m(2) Over a median follow-up of 8 years, 228 (6

11 of change in eGFR (-0.47 versus -0.32 ml/min per 1.73 m(2) per year; P<0.03).

12 s with moderately reduced eGFR (30-60 ml/min per 1.73 m(2)).

13 stimated glomerular filtration rates (mL/min per 1.73 m) of 43 to 72 (median, 55).

14 f using observed values (47.7 vs 38.6 mL/min per 1.73 m, P < 0.001) and was superior based on observe

15 andard cleaning strategies (n=76; 33.9 cases per 10 000 exposure days; relative risk [RR] 0.70, 95% C

16 , and presented them as excess relative risk per 10 mug/m(3) increase in particulate ambient air poll

17 F neutrophil counts (hazard ratio [HR], 1.10 per 10% increase; 95% confidence interval [CI], 1.04-1.1

18 tting stromal TILs as a continuous variable (per 10% increment).

19 rom an average of 208.8 tests to 143.0 tests per 10,000 patient-days (P < 0.001).

20 d from an average of 13.0 cases to 9.7 cases per 10,000 patient-days (P = 0.008).

21 vCDR asymmetry >/=0.20 are 1.44 times higher per 10-year increase in age (odds ratio [OR], 1.44; 95%

22 and gender-adjusted annual incidence of 1.8 per 100 000 (95% confidence interval, 1.3-2.2) between 1

23 d incidence rate of anaphylaxis was 26 cases per 100 000 person-years and the one-year period prevale

24 ly for men and women, by 7% (from 358 to 332 per 100 000 person-years; adjusted incidence ratio 0.93,

25 h the short-course regimen and 4.3 (2.9-7.6) per 100 000 population with continued use of longer ther

26 would be 3.3 (95% uncertainty range 2.2-5.6) per 100 000 population with the short-course regimen and

27 omes of the model were changes in life-years per 100 000 total population over 40 years (to 2050).

28 of whom 794 had sepsis (30.2 septic patients per 100 ICU beds, 95% CI 28.4-31.9).

29 incidence of VF on second-line ART was 12.9 per 100 person-years (n = 23), and prevalence of VF at c

30 ow-grade dysplasia (95% CI 1.5-7.2), and 7.3 per 100 person-years among patients with baseline high-g

31 0 person-years overall (95% CI 3.3-8.2); 3.3 per 100 person-years among patients with baseline low-gr

32 cidence rate of dysplasia recurrence was 5.2 per 100 person-years overall (95% CI 3.3-8.2); 3.3 per 1

33 bleeding event was 21.5 (95% CI, 15.4-29.1) per 100 person-years.

34 ons resulted in an overall incidence of 22.6 per 100 PYO (95% confidence interval [CI], 20.4-25.0).

35 under age 2 months (IQR, 1,712-2,076) to 791 per 100,000 (IQR, 683-915).

36 = 196 cases), 305 cases of HF remained (0.88 per 100,000 person-years).

37 n 2013, age-adjusted TBI mortality was 12.99 per 100,000 population (SE = 0.13).

38 cidence for these infants by 58%, from 1,878 per 100,000 subsequent children under age 2 months (IQR,

39 standardized incidence was stable around 11 per 100,000.

40 ed autoimmune disease affecting 20-50 people per 100,000.

41 ated to academic performance in adolescents (per 100-g increase in birth weight, -0.004 grade, 95% CI

42 ween predicted (hospital mean of 6.18 deaths per 1000 admissions based on preimplementation trends) a

43 ortality rates (hospital mean of 6.48 deaths per 1000 admissions; P=0.57).

44 ith diabetic retinal disease in 2009 to 13.6 per 1000 in 2015) while that of ranibizumab initially in

45 5964 DALYs (27 per 1000 individuals) were lost due to hip fractures, 12

46 Error rates with family reporting (45.9 per 1000 patient-days) were 1.2-fold (95% CI, 1.1-1.2) h

47 er than rates without family reporting (39.7 per 1000 patient-days).

48 person-years: 6.9 for SVR and 21.6 for NSVR per 1000 person-years.

49 of follow-up, indicating an incidence of 8.9 per 1000 person-years: 6.9 for SVR and 21.6 for NSVR per

50 er in the commercial population (weighted RD per 1000, -0.08; 95% CI, -0.51 to 0.36) or the Medicare

51 edicare Supplemental population (weighted RD per 1000, -0.45; 95% CI, -1.53 to 0.58).

52 were statistically significantly increased, per 10000 person-years, for gallbladder disease (30 more

53 Risks, per 10000 person-years, were significantly increased for

54 days of birth) were rare in all periods (5.2 per 100000 births in the baseline period, 1.9 per 100000

55 00000 births in the learning period, and 5.3 per 100000 births in the EOS calculator period) and did

56 er 100000 births in the baseline period, 1.9 per 100000 births in the learning period, and 5.3 per 10

57 rates were 1.49 per 100000 in the lung, 3.56 per 100000 in gastroenteropancreatic sites, and 0.84 per

58 00 in gastroenteropancreatic sites, and 0.84 per 100000 in NETs with an unknown primary site.

59 2012), the highest incidence rates were 1.49 per 100000 in the lung, 3.56 per 100000 in gastroenterop

60 se from 55.1 per 100000 person-years to 99.7 per 100000 person-years (P < .001 for trend).

61 d nearly 6-fold from 2001 to 2014 (from 0.26 per 100000 person-years to 1.51 per 100000 person-years)

62 4441) who experienced an increase from 55.1 per 100000 person-years to 99.7 per 100000 person-years

63 4 (from 0.26 per 100000 person-years to 1.51 per 100000 person-years).

64 in the US population sample was 0.10%, or 98 per 100000 persons (95% CI, 97-99 per 100000 persons).

65 10%, or 98 per 100000 persons (95% CI, 97-99 per 100000 persons).

66 1.02-1.84), and blood neutrophilia (HR, 1.06 per 109 neutrophils/L increase; 95% CI, 1.03-1.10).

67 ic masseter and temporalis muscle activities per 20-N bite-force (T20 N, microV), which defined thres

68 34% (IQR, 24% to 42%) (P < .001) (rate -3.3% per 5 years; IQR, -8.9% to 1.2%), indicating large inter

69 95% CI, 1.0 to 5.1; P = .04) and > 5 mitoses per 50 high-power fields (AHR, 2.5; 95% CI, 1.1 to 6.0;

70 For example, greater grip strength (per 6 kg) had an odds ratio (95% CI) of 0.85 (0.73-1.00)

71 ociated with colorectal cancer mortality [HR per 6.5 ppb=1.06 (95% CI: 1.02, 1.10).

72 Per a 10 leads to PAR-2 activation on BMDCs resulting in

73 e of p-STAT3(+) CD11c(+) cells was higher in Per a 10-administered mice and was reduced upon PAR-2 bl

74 ses of glacier ice involved a single element per ablation pass or spot.

75 The average mentoring cost per additional surgery for these 25 hospitals was $5.39.

76 Up to 46 per- and polyfluoroalkyl substances (PFASs) and precurso

77 More than 3000 per- and polyfluoroalkyl substances (PFASs) are, or have

78 dge gaps regarding the land-sea transport of per- and polyfluoroalkyl substances (PFASs) through rive

79 d with an estimated demand of one metric ton per annum for the prodrug, provides a compelling mandate

80 ncial payments amounted to a mean of $157177 per author.

81 o-thigh static scan with a 2-min acquisition per bed position was obtained.

82 s were used to establish 3 predictive models per binning configuration: one model based on a combinat

83 OSTAT food balance sheets for Australia, the per capita availability of added or refined sugars and s

84 Total per capita costs were $9506 for practices categorized as

85 Higher per capita density of health facilities resulted in a 25

86 Per-capita PMI spending was also associated with a modes

87 argest inpatient and outpatient cost impacts per case, followed by "other" cancer, whereas NMSC impac

88 siently incorporated in the mammalian genome per cell cycle.

89 e showed that the number of infection events per cell during cell-free HIV-1 infection follows a nega

90 is challenged with at least 100,000 lesions per cell on a daily basis.

91 ethod detected 21 798 CGIs (76% of all CGIs) per cell, and the number of CGIs consistently detected f

92 PM2.5 pollution in 2007 worldwide, about 12 per cent (411,100 deaths) were related to air pollutants

93 at in which the death occurred, and about 22 per cent (762,400 deaths) were associated with goods and

94 rt the detection of substantial (8.3 +/- 0.8 per cent from our most conservative simulation), variabl

95 Such low lattice misfit (0.03 +/- 0.04 per cent) decreases the nucleation barrier for precipita

96 ic ordering vector up to dopings of about 15 per cent.

97 The mean payment per charge was the same for men and women, $66 in 2012 a

98 entromere sequences typically occurring once per chromosome, a finding that helps to resolve nuclear

99 rth system climate sensitivity is K (1sigma) per CO2 doubling, which is notably higher than fast-feed

100 nge (10(2) 10(6)cells/mL) was 4.55x10(-2)muA per concentration decade, with the lowest detection limi

101 y and processes 30 million name-strings/hour per CPU thread.

102 utron density in near-Earth space-2 x 10(-9) per cubic centimetre-confirming theoretical estimates.

103 ndicate that energy use and carbon footprint per cubic meter of wastewater treated, varies markedly w

104 remely high number density (more than 10(24) per cubic metre) and small size (about 2.7 +/- 0.2 nanom

105 uzumab ozogamicin (starting dose 1.8 mg/m(2) per cycle [0.8 mg/m(2) on day 1; 0.5 mg/m(2) on days 8 a

106 000 cycles with capacity fade of only 0.001% per cycle.

107 s of adjunctive rifampicin (600 mg or 900 mg per day according to weight, oral or intravenous) versus

108 The mean numbers of cigarettes smoked per day at 2 weeks and 1-month were significantly lower

109 ient self-reported, estimates of steps taken per day correlated with smartphone data (surrogates: n =

110 g hydroxyurea to placebo at 20 +/- 2.5 mg/kg per day for 12 months.

111 ce per day for 7 days, followed by 0.5 mg/kg per day for 3 days).

112 Escitalopram was given at a dose of 10 mg per day for 3 weeks and 20 mg per day thereafter.

113 topically to a designated target lesion once per day for 4 consecutive days on days 1 through 4, 8 th

114 e placebo or hydrocortisone (0.5 mg/kg twice per day for 7 days, followed by 0.5 mg/kg per day for 3

115 In wild-type (WT) mice, LY2828360 (3 mg/kg per day i.p. x 12 days) suppressed chemotherapy-induced

116 y still had doses equivalent to five tablets per day of 5-mg hydrocodone.

117 y translated into standard drink equivalents per day of different countries, the WHO risk levels coul

118 otentially, targets will be consumed at 1 M per day per reactor, demanding a 5000x unit cost reducti

119 dose of 10 mg per day for 3 weeks and 20 mg per day thereafter.

120 DSM criteria), smoking 10 or more cigarettes per day, and a willingness to attempt smoking cessation.

121 To support adherence to 8 cups of water per day, the water group received well-defined messages

122 terms of mean ethanol consumption (in grams) per day.

123 LY) gained, pound372 207 (268 162-1 903 385) per death averted, and pound628 874 (434 902-4 740 724)

124 n significant positive growth trends of 1-2% per decade for the full period, and 3-7% since 1950.

125 lians, increasing age (odds ratio [OR], 1.72 per decade) and having not had an eye examination within

126 glycemia with a blood glucose level of 55 mg per deciliter (3.1 mmol per liter) or below was signific

127 eratures decreased yields by 0.8% (10 kg/ha) per degrees C.

128 nsistent with binding of one molecule of 11m per dimer interface, contrary to most benzothiadiazine d

129 n estimate of US$94 (95% CrI: US$51, US$166) per Disability Adjusted Life Year (DALY) averted, PMI-fu

130 e spent using the EHR was 10.8 (5.0) minutes per encounter (range, 5.8-28.6 minutes).

131 transitions and emission of several photons per excitation comprise a very attractive feature of sem

132 0.98; p<0.001) and clinical benefit (OR 0.95 per extra year, 0.92-0.98; p=0.004).

133 lihood of complete clinical success (OR 0.95 per extra year, 0.93-0.98; p<0.001) and clinical benefit

134 The mean number of retinal tears per eye was 1.36 +/- 0.5 (range = 1-2); bilateral retina

135 nical management (median number of OCT scans per eye, 5; range, 1-15).

136 sters (SiPcs, 1-7) with non-, partially- and per-fluorinated aliphatic (linear or branched at the alp

137 if they can be priced below around pound200 per fully protected person.

138 own as Pf EMP1 encoded by up to 60 var genes per genome.

139 ng with its extremely low cost (about 3 cent per gram), simplicity of fabrication and environment-fri

140 0.2 vs. 3.6 +/- 0.4 percentage injected dose per gram).

141 1, 2, 3, 4, 5, or 6 weeks of storage (n = 10 per group).

142 verted, and pound628 874 (434 902-4 740 724) per HIV transmission averted.

143 ecision making (mean, 9.70 vs 2.77 instances per hour, P = .03) and failure to progress (mean, 1.20 v

144 re to progress (mean, 1.20 vs 0.13 instances per hour, P = .04) were addressed, and they were more th

145 olus of intravenous fluids (odds ratio, 1.01 per hour; 95% CI, 0.99 to 1.02; P=0.21).

146 inistration of antibiotics (odds ratio, 1.04 per hour; 95% CI, 1.03 to 1.06; P<0.001) but not a longe

147 sted in-hospital mortality (odds ratio, 1.04 per hour; 95% confidence interval [CI], 1.02 to 1.05; P<

148 adjusted to one or two biotin binding sites per immobilized SAv by choosing appropriate surface chem

149 o, where dI is the number of intergenic SNPs per intergenic site.

150 ces in running speed, as the firing rates of PER interneurons did not show significant velocity modul

151 stimating equations estimated relative risks per interquartile-range increment for pollutants and hig

152 ge amounts wasted, while the specific impact per kg is largest for beef.

153 d sex-adjusted hazard ratio 1.05 [1.04-1.06] per kg/m(2), P<0.001).

154 = 1.31 [95% confidence interval = 1.05-1.63] per kJ/m(2)) and minimum (1.25 [1.06-1.47] per kJ/m(2))

155 ] per kJ/m(2)) and minimum (1.25 [1.06-1.47] per kJ/m(2)) UVR dose exposure.

156 ypically from tens to hundreds of dead trees per km(2) , rising dramatically during the fourth year o

157 seline platelet count (<10 x 10(9) platelets per L vs >/=10 x 10(9) platelets per L) and disease (MDS

158 ) platelets per L vs >/=10 x 10(9) platelets per L) and disease (MDS vs AML).

159 let count of lower than 30 x 10(9) platelets per L, aged at least 18 years, with refractoriness, inel

160 ucose level of 55 mg per deciliter (3.1 mmol per liter) or below was significantly lower in the sotag

161 ubles mean litter size to about nine piglets per litter.

162 sistence time for species by a factor of 6.8 per location or approximately 2,272 years, on average, r

163 (beta=0.13 BMI z-score (95% CI: 0.01, 0.25) per log increase of p,p'-DDE).

164 els were identified (median 2; quartiles 1-3 per map), although this represented LR in only n=7 out o

165 a high density of chemical synapses, about 1 per microm(3) in the mammalian cerebral cortex.

166 (decrease of 2.02+/-2.32 vs. 0.56+/-1.39 ng per milliliter, P=0.02).

167 es at levels ranging from 0.1 to 10(5) parts per million (weight/weight), worked equally well on diff

168 sociated with NSVT runs at a rate >200 beats per minute (adjusted hazard ratio, 15.63; 95% confidence

169 ) mL/kg per minute to 16.1 (13.2-18.6) mL/kg per minute (P=0.009 for within-group changes), whereas n

170 ment in peak Vo2 from 14.5 (10.5-16.6) mL/kg per minute to 16.1 (13.2-18.6) mL/kg per minute (P=0.009

171 tching beats from 35+/-4.3 to 65+/-4.0 beats per minute.

172 age oxygen consumption was 1.1 +/- 0.2 mL/kg per minute.

173 ion of participants with less than 50 copies per mL of plasma HIV-1 RNA at week 48 (by the US Food an

174 UTIs with 10(3) or more colony-forming units per mL of vaccine-serotype E coli was noted in the vacci

175 irological suppression (HIV-1 RNA <50 copies per mL) at week 24.

176 logical suppression (<50 copies of HIV-1 RNA per mL) on a stable regimen for at least 6 months, CD4 c

177 % or greater reduction in mean migraine days per month, change in the number of days of use of acute

178 toes at spore dosages as low as one conidium per mosquito.

179 il vein injection (150 mug of each conjugate per mouse) at 1, 7 and 13 days post-injection.

180 D4 count decreased by a median of -130 cells per muL (range -472 to 266) with little change in CD4 ce

181 s with CD4 cell count of more than 500 cells per muL assigned to immediate ART or deferral until thei

182 t 6 months, CD4 count of more than 100 cells per muL, and no history of resistance to elvitegravir, e

183 ir CD4 cell counts were lower than 350 cells per muL.

184 p of active ECC couplons (on average, 17,000 per myocyte).

185 s of active pharmaceutical ingredients (API) per nano-liposome that enable therapeutically viable API

186 In contrast, the number of inputs per neuron in cerebral cortex is more uniform and large.

187 receive either two intranasal doses (0.25 mL per nostril) of LAIV H5N2 (101 participants) or placebo

188 ck Study, multivariable adjusted risk ratios per one-SD higher log miR-122 were 1.60 (95% CI 1.30-1.9

189 ctive, and liberates more than 120 equiv NH3 per Os center in a single batch experiment using Cp*2Co

190 (odds ratio [OR]: 0.992; 95% CI 0.984-1.000 per pack-year) and positively with obesity: OR: 1.97 [1.

191 eal injection of AAV2(Y444,500,730F)-P1ND4v2 per participant.

192 number of potentially actionable alterations per patient being 2 (range, 0-13).

193 ere the difference of total episode payments per patient between lowest and highest quintile hospital

194 nged survival; the mean number of life-years per patient was 19.4 in the scenario with IR compared wi

195 The numbers of days on antibiotic(s) per patient were 1.73 in the cases and 2.12 in the contr

196 We included one isolate per patient.

197 d 19 rotor domains in 10 patients (1.8+/-1.1 per patient; 7 in the right atrium versus 12 in the left

198 etween imaging and oncology specialists on a per-patient basis.

199 e resource settings yields 0.008 fewer QALYs per person, but saves US$204 compared to monitoring ever

200 core samples to 50 x 10(6) autologous cells per pig.

201 geons received a mean dose of 34 +/- 15 muSv per procedure.

202 after applying a 3-year lag period (OR, 1.09 per procedure; 95% CI, 1.03-1.14 and OR when exposure fr

203 most smoking-related cancer cases (OR, 1.10 per procedure; 95% CI, 1.05-1.16 and OR when exposure fr

204 stintervention (n = 146) parent surveys in a per protocol analysis of evaluable parents.

205 Analyses were done per protocol for all patients who commenced drug and inc

206 ty were estimated for intention-to-treat and per-protocol analyses.

207 = 0.09) and a significant -3.8% reduction in per-protocol analysis (P = 0.043).Independent of other l

208 Per-protocol analysis revealed no difference between the

209 of clinical resolution of cellulitis in the per-protocol analysis.

210 In the per-protocol population (n=58), the primary and most sec

211 val for treatment difference, -0.23 to 0.66; per-protocol population).

212 e primary efficacy endpoint, analysed in the per-protocol population, was pathological complete respo

213 The confirmatory analysis using the per-protocol sample (n = 153) failed to show noninferior

214 id our primary and secondary analyses in the per-protocol set, which excluded patients with non-compl

215 io (ICER) was euro6840.75 (95% CI 2545-2759) per QALY gained for a treatment efficacy of 20% and euro

216 for a treatment efficacy of 20% and euro4243 per QALY gained for treatment efficacy of 50%.

217 ost US$18,000 (95% CI: US$14,000, US$24,000) per QALY gained, 50% NSP coverage could avert up to 35,0

218 cost US$25,000 (95% CI: US$7,000, US$76,000) per QALY gained, 50% Test & Treat coverage could avert u

219 ost US$27,000 (95% CI: US$15,000, US$48,000) per QALY gained, and 50% PrEP coverage could avert up to

220 US$300,000 (95% CI: US$162,000, US$667,000) per QALY gained.

221 747, yielding an unfavorable ICER of $154684 per QALY.

222 tiveness ratios (ICERs) in 2015 U.S. dollars per quality-adjusted life year (QALY) gained and number

223 incremental cost-effectiveness ratios (cost per quality-adjusted life year gained) from the societal

224 2 201 (95% credible interval 12 662-132 452) per quality-adjusted life-year (QALY) gained, pound372 2

225 tly estimate the number of DNA target copies per reaction partition, lambda, where the partitions are

226 ly, targets will be consumed at 1 M per day per reactor, demanding a 5000x unit cost reduction to $

227 ciative learning (-0.140 standard deviations per risk factor, p < 0.0001) and remained significant af

228 via multiparametric MR imaging (31 mutations per sample +/- 15), and high-grade cancer (33 mutations

229 +/- 15), and high-grade cancer (33 mutations per sample +/- 18) (P = .30).

230 l via histopathologic analysis (34 mutations per sample +/- 19), mildly suspicious via multiparametri

231 via multiparametric MR imaging (37 mutations per sample +/- 21), intermediately suspicious via multip

232 assays that produce hundreds of measurements per sample are powerful tools for quantifying cell-mater

233 nalysis time to be reduced to less than 55 s per sample.

234 azard ratios (HRs) for incident parkinsonism per SD decrease in global cognition, adjusted for age, s

235 ntinuous variables, and results are reported per SD increase of each lipid fraction.

236 othripsis and associated with poor prognosis per se and not merely by association with other adverse

237 red with younger subjects, chronological age per se did not correlate with rationality measures withi

238 In seeds, germination per se is not affected in seipin2 seipin3 and triple sei

239 did not impair spatial learning or retrieval per se, but impaired the ability to follow changing spat

240 indicating that it reflects gene activation per se.

241 velocity offsets of less than 600 kilometres per second and linear offsets of less than 100 kiloparse

242 We present an all-plasmonic 116-gigabits per second electro-optical modulator in which all the el

243 10 kilobases at a velocity of 60 base pairs per second.

244 for four loci, in three PacBio runs (one run per set).

245 SNPs with low LLD have significantly larger per-SNP heritability and that roughly half of this effec

246 al existing methods when there is one allele per species, although STELLS2 is slower than these metho

247 imab maintenance therapy at a dose of 375 mg per square meter of body-surface area administered every

248 gold foil with a sheet resistance of 7 ohms per square showed only a 4% increase in resistance after

249 material-enhanced volume scans were acquired per stenosis.

250 CAPZB, present at approximately 100 copies per stereocilium, concentrated at stereocilia tips as ha

251 n of busulfan dose was successfully achieved per study design.

252 lity was assessed using established methods, per study design.

253 n the number of annual total thyroidectomies per surgeon and risk of complications.

254 d number of unnecessary treatments generated per TB death averted, if standard Xpert were switched to

255 All diagnoses were adjudicated as per the universal definition of myocardial infarction.

256 sition allows standard uncertainties of 0.18 per thousand and 0.48 per thousand to be achieved for de

257 cross the entire analytical procedure is 0.6 per thousand for delta(15)N and 0.5 per thousand for del

258 e is 0.6 per thousand for delta(15)N and 0.5 per thousand for delta(18)O.

259 uncertainties of 0.18 per thousand and 0.48 per thousand to be achieved for delta(13)C and delta(18)

260 Annual mortality risk per thousand tons of precursor emissions (health damage

261 ption and the known role of PDF in enhancing PER/TIM stability occur via independent pathways downstr

262 A content can produce about 50 kg of alkenes per tonne of suspended solids treated, with a significan

263 tal tree burden of summation operator26PFASs per tree was up to 11 mg for birch and 1.8 mg for spruce

264 o of mean tumor to bone marrow absorbed dose per unit administered activity of (131)I, after THW and

265 shrubs delivered the largest amount of heat per unit area.

266 Leaf dry mass per unit leaf area (LMA) is a central trait in ecology,

267 than the resin with fewer ion-exchange sites per unit mass.

268 n PAWP were measured to calculate the DPD as per usual practice (diastolic pulmonary artery pressure-

269 E (MMAE) significantly increase loading on a per-vehicle basis as compared to antibody-drug conjugate

270 The overall per-vessel diagnostic accuracy of FFR-CT was 81.9% (95%

271 The specific infectivities (PFU per viral genome) of HSV(chol) and HSV(des) were similar

272 number of envelope glycoprotein (Env) spikes per virion, i.e., approximately 7 to 14.

273 CI, -0.15 to 0.92) or metabolic equivalents per week (3 studies; standardized mean differences, 0.11

274 once weekly at 8 and 10 mg/kg, or two times per week at 4 and 6 mg/km on weeks 1 and 2 of 3-week rep

275 nterventions significantly increased minutes per week of metabolic equivalents (4 studies; standardiz

276 nterval [CI], 1.44 to 2.69), but not minutes per week of MVPA (13 studies; standardized mean differen

277 juvant potent topical corticosteroids (<30 g per week) were permitted during weeks 1-3.

278 2010 to calculate the hospitalization costs per year attributed to misdiagnosed lower extremity pseu

279 ard of mortality remained, but decreased 14% per year for DDKT recipients (0.830.860.89, P < 0.001) a

280 recipients (0.830.860.89, P < 0.001) and 9% per year for LDKT recipients (0.850.910.98, P < 0.001).

281 ging utilization went from 0.43 examinations per year in 2007 to 0.34 examinations per year in 2013,

282 ations per year in 2007 to 0.34 examinations per year in 2013, a decrease of 21.33% (P < .0001).

283 D) SMR was 0.46 (1.06) vs 0.50 (1.50) events per year in the every 4 weeks vs every 12 weeks groups (

284 In addition, there was a 9.8% increase per year in the incidence rate of food-related anaphylax

285 ed in delayed-start patients (from -2.26 g/L per year to -1.26 g/L per year), but no significant diff

286 patients during this time period (-1.51 g/L per year to -1.63 g/L per year), thus in early-start pat

287 dily increased yields by about 1% (13 kg/ha) per year while increasing temperatures decreased yields

288 K9 inhibitors in the United States (>$14,500 per year) are >100x higher than generic statins, and onl

289 rate (mean number of skeletal-related events per year), and, in a subset of 553 patients, suppression

290 tients (from -2.26 g/L per year to -1.26 g/L per year), but no significant difference was seen in the

291 time period (-1.51 g/L per year to -1.63 g/L per year), thus in early-start patients the efficacy was

292 disease progression to recovery (median 16% per year, 95% uncertainty range 11%-21%).

293 rine ecosystems, fix up to 27.4 Tg of carbon per year, and provide important structural components fo

294 of passive sampling for 1-week periods twice per year, coinciding with lung function testing.

295 omes from MIPD, with a threshold of 22 cases per year.

296 t could prevent approximately 107 500 deaths per year.

297 GFR (-0.47 versus -0.32 ml/min per 1.73 m(2) per year; P<0.03).

298 ere significantly reduced (40 deaths [0.025% per year] v 94 deaths [0.038% per year]; HR, 0.65; 95% C

299 deaths [0.025% per year] v 94 deaths [0.038% per year]; HR, 0.65; 95% CI, 0.45 to 0.94; P = .02) by t

300 ed forests and, unexpectedly, increased 4.9% per yr from 1996 to 2014, likely indicating a recovery f